螨变应原注射液联合常规药物治疗支气管哮喘患儿的效果

Effects of Novo-Helisen-Depot combined with conventional drugs in treatment of children with bronchial asthma

目的:观察螨变应原注射液联合常规药物治疗支气管哮喘患儿的效果。方法:选取2018年1月至2019年6月该院收治的80例支气管哮喘患儿进行前瞻性研究,按照抽签法将其分为对照组与观察组各40例。对照组予以常规药物(孟鲁司特钠+硫酸沙丁胺醇+布地奈德)治疗,观察组在对照组基础上联合螨变应原注射液治疗,共治疗3年。比较两组临床疗效,治疗前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、呼气流量峰值(PEF)、FEV_(1)/FVC]水平、血清炎性因子[白细胞介素-6(IL-6)、IL-8、肿瘤坏死因子-α(TNF-α)]水平、免疫球蛋白E(IgE)水平和鼻部症状评分,以及不良反应发生率。结果:观察组治疗总有效率为95.00%(38/40),高于对照组的75.00%(30/40),差异有统计学意义(P<0.05);观察组FEV_(1)、FVC、FEV_(1)/FVC、PEF水平均高于对照组,差异有统计学意义(P<0.05);观察组血清IL-6、IL-8、TNF-α、IgE水平均低于对照组,差异有统计学意义(P<0.05);观察组鼻塞、鼻痒、喷嚏、流涕等鼻部症状评分均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:螨变应原注射液联合常规药物治疗支气管哮喘患儿可提高治疗总有效率和肺功能指标水平,降低血清炎性因子水平、IgE水平和鼻部症状评分,效果优于单纯常规药物治疗。

Objective:To observe effects of Novo-Helisen-Depot combined with conventional drugs in treatment of children with bronchial asthma.Methods:A prospective study was conducted on 80 children with bronchial asthma admitted to this hospital from January 2018 to June 2019.They were divided into control group and observation group according to the lottery method,40 cases in each.The control group was treated with conventional drugs(Montelukast sodium+Salbutamol sulfate+Budesonide),while the observation group was treated with Novo-Helisen-Depot on the basis of that of the control group.The treatment lasted for 3 years.The clinical efficacy,the lung function index levels[forced vital capacity(FVC),forced expiratory volume in one second(FEV_(1)),peak expiratory flow(PEF),FEV_(1)/FVC],the inflammatory factor levels[interleukin-6(IL-6),IL-8,tumor necrosis factor-α(TNF-α)],the immunoglobulin E(IgE)level and the nasal symptom score,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the observation group was 95.00%(38/40),which was higher than 75.00%(30/40)in the control group,and the difference was statistically significant(P<0.05).The levels of FEV_(1),FVC,FEV_(1)/FVC and PEF in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of IL-6,IL-8,TNF-αand IgE in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The scores of nasal symptoms such as nasal congestion,nasal itching,sneezing and runny nose in the observation group were lower than those in the control group,and the diferences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Novo-Helisen-Depot combined with conventional drugs in the treatment of the children with bronchial asthma can improve the total effective rate of treatment and the levels of lung function indexes,and reduce the levels of inflammatory factors,IgE levels and nasal symptom scores.Moreover,it is superior to single conventional drug therapy.